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Paraoxonase-1 (PON1) is an HDL cholesterol–associated
antioxidant enzyme, and some of its polymorphisms are
linked with systemic oxidative stress and cardiovascular
events. In this study, we genotyped seven single nucleotide
polymorphisms (SNPs) within the PON1 gene and determined
their association with chronic kidney disease in 2,968
individuals from the general Japanese population. We found
that a missense SNP (rs662) with a G-to-A substitution
leading to an amino acid substitution (G[Arg]/A[Gln]), was
significantly associated with albuminuria and estimated
glomerular filtration rate (eGFR), especially in women. The
A/A genotype in women had the highest prevalence of
albuminuria and the lowest values of adjusted eGFR. In
contrast, such relationships were not detected in men.
Multivariate regression analysis found that the A/A genotype
was an independent and significant factor for albuminuria
and renal insufficiency (eGFR less than 60 ml/min/1.73 m2).
The serum PON1 activity was lowest in subjects with the
A/A genotype. In biopsy specimens, immunohistochemical
analysis found increased PON1 expression on the endothelial
surface of sclerotic renal arterioles and glomerular capillaries
in patients with hypertension or diabetes. Our study shows
that this PON1 G-to-A substitution may be a key player in
a common pathway to chronic kidney and cardiovascular
diseases in women.
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Chronic kidney disease (CKD) is recently attracting the
attention of clinicians because of high prevalence in the
general population. Especially, its relation with cardiovascu-
lar diseases (CVD) observed in several epidemiological
studies has a wide influence on daily practice.1,2 The
common diseases including CVD and CKD are multifactorial
disorders affected by various environmental and genetic
factors. The risk factor analyses for the development of renal
insufficiency showed that the environmental risk factors such
as hypertension, hyperglycemia, dyslipidemia, smoking, and
oxidative stress are involved.3,4 Conversely, little is known
about genetic factors.
Oxidative stress is induced by various metabolic disorders
and plays an important role in the pathogenesis of
atherosclerosis. An antioxidative agent is considered to
attenuate the progression of vascular injury. Paraoxonase-1
(PON1), one of the enzymes with antioxidative properties, is
a high-density lipoprotein–associated enzyme that promotes
the function of high-density lipoprotein (that is, antioxida-
tion, anticoagulation, and anti-inflammation). It is reported
that serum PON1 activity was decreased in patients with
atherosclerosis, Alzheimer’s disease, and chronic renal fail-
ure.5–8 Recently, Bhattacharyya et al.9 reported that the
genotype of PON1 is associated with serum PON1 activity,
systemic oxidative levels and cardiovascular events. These
observations suggest a possibility that PON1 might be
involved in a wide range of diseases induced by oxidative
stress.
However, it is unknown whether the PON1 genotype is
related to the development of chronic kidney disease. In this
study, we examined the relation between renal function,
urine albumin excretion, and PON1 in the Japanese general
population.
RESULTS
Characteristics of subjects
Baseline characteristics of 2968 subjects who entered into a
final analysis were as follows; mean age was 63.0±10.5 years
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old, 1343 men (45.2%), 1629 subjects (54.9%) with
hypertension, 234 subjects (7.8%) with diabetes, 895 subjects
(30.2%) with obesity, 988 subjects (33.3%) with hypercho-
lesterolemia, and 653 subjects (22.0%) with albuminuria.
Polymorphisms in PON1 genes examined in this study
PON1 gene is located on chromosome 7q21–q22. We have
selected seven single nucleotide polymorphisms (SNPs)
regarding PON1 genes that displayed frequent minor allele
frequencies in Japanese from dbSNP database of the NCBI
and International HapMap Project as described in Materials
and Methods section. The chromosomal locations of these
seven SNPs are shown in Figure 1 and their characters are
summarized in Table 1.
To examine linkage disequilibrium (LD) of the PON1
gene, we performed LD analysis using seven SNP typing data.
We observed a consistency of genotypes between SNP5 and
SNP7, rs622G/A, rs2269829C/T and rs854555T/G, by detect-
ing a linkage disequilibrium (D040.85 and r240.70)
(Figure 2). It is well known that the missense SNP5 rs662
with amino acid substitution is related to paraoxonase
activity and the LD analysis demonstrated that the surround-
ing SNP6 and SNP7 were in LD block with SNP5 in this
population. Therefore, we hereafter focused this SNP5 rs662
and examined its relation with albuminuria and renal
function. The comparison of basal characters in subjects
with rs662 genotypes A/A, A/G, and G/G was shown in
Table 2. There was no significant difference in the basal
characters among subjects with these genotypes except uric
acid levels.
Association of PON1 SNP rs662 genotype with albuminuria
and eGFR
First we examined the relationship between rs662 genotypes
and urine albumin excretion. The prevalence of albuminuria
was significantly related to rs662 genotypes with highest
value in A/A genotype (A/A: 27.9, A/G: 22.2, and G/G:
21.1%, respectively, P¼ 0.0327) in total subjects. Further
analysis revealed the gender difference in the relation. In
women A/A genotype showed the strikingly high prevalence
as compared with other genotypes (A/A: 32.5, A/G: 21.8 and
G/G: 19.5%, P¼ 0.0017). In contrast, there was no significant
difference between genotypes in men (Figure 3a). The levels
of urine albumin–creatinine ratio showed a similar tendency
that the significant relation was observed in women, but not
in men (Figure 3b).
Next, we examined the relationship between genotype of
rs662 and renal function. To exclude the effects of covariates
we adjusted estimated glomerular filtration rate (eGFR) for
age, gender, body mass index, systolic blood pressure, total
protein, total cholesterol, triglyceride, uric acid, HbA1c,
hemoglobin, smoking, and drinking, using a general linear
model. Then, we performed quantitative trait locus analysis
of population having this SNP and adjusted eGFR by an
analysis of variance (ANOVA). This analysis showed that
adjusted eGFR levels were significantly associated with rs662
genotypes in women. The eGFR values of population having
SNP rs662 A/A, A/G, and G/G were 78.7±0.5, 79.5±0.2,
and 80.2±0.2 ml/min per 1.73 m2 (mean±s.e.), respectively
(P¼ 0.0139). Again, such a relation was not observed in men
(Figure 4). These relationships between renal function,
albuminuria, and rs662 genotype were preserved in non-
diabetic population after excluding diabetic subjects (data
not shown).
Further, to examine the independent relation of rs662
genotype with albuminuria and renal insufficiency (eGFR
o60 ml/min per 1.73 m2), we performed multivariate logistic
regression analysis including age, gender, hypertension,
diabetes, obesity, smoking, drinking, and hypercholesterolemia.
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Figure 1 | The chromosomal locations of SNPs in PON1 gene.
Coding exons are represented by thick blocks connected by bold
lines representing introns. The 50 and 30 untranslated regions are
displayed as thinner blocks on the leading and trailing ends of the
aligning regions. SNP1, rs3917527; SNP2, rs2057681; SNP3,
rs3917538; SNP4, rs3917541; SNP5, rs662; SNP6, 2269829; SNP7,
rs854555.
Table 1 | Polymorphisms in PON1 genes examined in the study
NCBI SNP Public location
Allele Allele frequency Genotype
SNP ID reference SNP type position (B36.2) 1 2 Allele 1 Allele 2 11 12 22 Heterozygosity
SNP1 rs3917527 intron 5 94778194 A G 0.88 0.12 2274 649 44 0.22
SNP2 rs2057681 intron 5 94776193 C T 0.66 0.34 1290 1350 326 0.45
SNP3 rs3917538 intron 5 94775829 T C 0.53 0.47 822 1492 653 0.50
SNP4 rs3917541 intron 5 94775560 C T 0.88 0.12 2264 647 44 0.22
SNP5 rs662 missense 94775382 G(Arg) A(Gln) 0.66 0.34 1287 1351 327 0.45
SNP6 rs2269829 intron 6 94774065 C T 0.65 0.35 1249 1369 345 0.45
SNP7 rs854555 intron 8 94778327 T G 0.65 0.35 1222 1335 360 0.46
NCBI, National Center for Biotechnology Information; PON1, paraoxonase-1.
allele 1, major allele; allele 2, minor allele.
Typing call rates were over 99% The Hardy–Weinberg equilibrium P-values did not deviate in all SNPs (P40.1).
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It demonstrated that the rs662 A/A genotype was an
independent factor for albuminuria (odds ratio 1.432
(95%CI 1.091–1.879), P¼ 0.0096) and renal insufficiency
(odds ratio 1.503 (95%CI 1.016–2.224), P¼ 0.0412) (Table 3).
The paraoxonase activity in rs662 genotype
To confirm the relationship between rs662 genotypes and the
enzymatic activity of PON1, we measured paraoxonase
activities in 150 subjects that their basal characters were
matched (A/A: n¼ 60, A/G: n¼ 45, and G/G: n¼ 45,
respectively). It revealed that paraoxonase activity was related
to rs662 genotype and the A/A genotype had the lowest
activity (Figure 5). This relation was observed both in men
and women. We also examined the levels of malondialde-
hyde-LDL, one component of oxidized LDL in these subjects.
However, there was no significant difference among them
(A/A: 145.6±50.6, A/G: 160.0±50.6, and G/G: 165.3±50.2
U/L [mean±s.d.], P¼ 0.1170).
The localization of PON1 expression in human renal
specimen
Finally, we investigated the localization of PON1 expression
in human kidney using immunohistochemical method. In
human biopsy specimen, the expression of PON1 was
strongly detected in vascular endothelial surface in sclerotic
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Figure 2 | Linkage disequilibrium (LD) analysis of seven SNPs in PON1, as measured by D0 (a) and r2 (b). Dark squares signify high LD
values. SNP1, rs3917527; SNP2, rs2057681; SNP3, rs3917538; SNP4, rs3917541; SNP5, rs662; SNP6, 2269829; SNP7, rs854555.
Table 2 | Genotype-based comparisons of basal
characteristics in rs662
rs662 Genotypes A/A A/G G/G P-value
Number 326 1350 1287
Men (%) 50.0 44.0 45.3 NSa
Age (years) 62.9±9.9 63.0±10.3 63.0±10.3 NSb
Drinker (%) 45.4 40.0 41.9 NSa
Current smoker (%) 20.2 17.4 19.1 NSa
Hypertension (%) 55.2 53.9 55.8 NSa
Diabetes (%) 7.7 7.7 8.2 NSa
Hypercholesterolemia (%) 32.5 33.8 32.9 NSa
Obesity (%) 30.7 29.6 30.5 NSa
Systolic BP (mm Hg) 134.7±15.1 133.6±16.1 134.7±15.7 NSb
Diastolic BP (mm Hg) 79.9±9.7 78.9±10.2 79.6±9.9 NSb
Serum creatinine
(mg/100 ml)
0.70±0.16 0.67±0.16 0.68±0.29 NSb
Hemoglobin A1c (%) 5.25±0.70 5.24±0.65 5.25±0.69 NSb
HDL-C (mg/100 ml) 59.4±14.9 59.2±14.8 58.9±14.1 NSb
LDL-C (mg/100 ml) 123.5±29.0 125.0±30.3 123.5±29.3 NSb
Triglyceride (mg/100 ml) 108.0±77.0 106.4±63.5 106.4±60.1 NSb
Uric acid (mg/100 ml) 5.2±1.4 5.1±1.3 5.0±1.4 0.015b
Hemoglobin (g/100 ml) 13.8±1.6 13.7±1.4 13.7±1.4 NSb
Past history of CVD (%) 12.3 11.1 13.7 NSa
BP, blood pressure; CVD, cardiovascular disease; HDL-C, high-density lipoprotein-
cholesterol; LDL-C, low-density lipoprotein cholesterol; NS, not significant.
aw2 test.
bAnalysis of variance, Mean±s.d.
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Figure 3 | The association between rs662 genotype and urine
albumin excretion. (a) The prevalence of albuminuria. P-value
shows the comparison among rs662 genotypes by a w2 test. (b)
Urine albumin–creatinine ratio. P-value shows the comparison
among rs662 genotypes by non-parametric Kruskal–Wallis test.
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Figure 4 | Genotype-based association of PON1 with eGFR.
Estimated GFR was expressed as mean±s.e. P-value shows the
comparison among rs662 genotype by analysis of variance with
Bonferroni test as a post hoc test. NS; not significant.
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renal arterioles and glomerular capillaries in subjects with
hypertension (Figure 6a) and diabetes (Figure 6b). In normal
specimen obtained from renal tumor section, PON1 expres-
sion was scarcely observed (data not shown).
DISCUSSION
In this study, we have revealed for the first time the
association between albuminuria, renal function, and PON1
genotype in the Japanese female population. This result
suggests that genetic variation of PON1 might affect the
development of chronic kidney disease as well as cardiovas-
cular diseases.
The evidence that PON1 has an antioxidant effect and
vasoprotective properties, has been provided by studies using
transgenic mice.5,6 Furthermore, the relation of serum PON1
activity with vascular damages was reported in several clinical
studies.10,11 Chronic kidney diseases belong to a category of
vascular diseases, therefore, it is speculated that PON1 might
play a part in the development of CKD. This study showed
that the PON1 genotype was associated with estimated GFR
and the prevalence of albuminuria in women. A histological
study revealed a PON1 expression in damaged renal vessels.
These findings suggest that PON1 genotype might affect
vascular damage by modulating its antioxidative capacity and
could be one of the common genetic factors for various kinds
of vascular diseases.
The PON1 activity is mostly regulated by its genotypes
and the SNP rs662 genotype accompanying amino acid
substitution is related to its enzymatic activity (high in G/G
genotype and low in A/A genotype).12 Theoretically, SNP
rs662 A/A genotype has a lower antioxidative effect and less
vasoprotective property. However, which genotype of PON1
rs662 is a risk factor for cardiovascular diseases has been
controversial,13 because of a lack of the study that
concomitantly examined PON1 genotype, its enzymatic
activities, blood oxidative status, and vascular damages in
humans. Recently, Bhattacharyya et al.9 revealed a systematic
evidence that PON1 genotype SNP rs662 A/A was related to
lower PON1 activity, higher plasma oxidative stress, and poor
CVD prognosis. In accordance with Bhattacharyya’s report,
our result showed that rs662 A/A genotype with a low
paraoxonase activity was a risk factor for albuminuria and
renal insufficiency in women. These findings suggest that
rs662 A/A genotype might be used as a common risk allele
for CKD and CVD.
In the development of CKD, the interaction between
environmental and genetic factors plays an important role. A
previous study has revealed the significance of environmental
factors including hypertension, diabetes, obesity, and smok-
ing.3 In contrast, the analysis in a genetic effect is still limited.
Pinto-Sietsma et al.14 has reported the association between
Endothelin-1 genotype and renal impairment in general non-
diabetic population in Netherlands. In our previous study, we
found that the genotype of inflammatory chemokine, CC
chemokine ligand 5 is associated with urine albumin
excretion.15 This study further showed that the PON1
genotype was independently related to albuminuria and
renal function even after adjusting for conventional risk
factors. These observations suggest that the genetic factor
might be involved in the development of CKD in a general
population by affecting renal vascular damages. Of note,
there is a possibility that PON1 genotype might have an
indirect pathway to induce vascular damages by modulating
other risk factors such as lipid metabolism and blood
Table 3 | Odds ratio of rs662 genotype for albuminuria and
renal insufficiency (eGFR o60 ml/min per 1.73 m2)
Unadjusted Adjusteda
OR (95% CI) P-value OR (95% CI) P-value
Albuminuria
rs662 A/A 1.397 (1.076–1.813) 0.0119 1.432 (1.091–1.879) 0.0096
Renal insufficiency (eGFRo60 ml/min per 1.73 m2)
rs662 A/A 1.427 (0.977–2.083) 0.0657 1.503 (1.016–2.224) 0.0412
OR, odds ratio.
aAdjusted for gender, age, drinking, smoking, obesity, diabetes, hypertension, and
hypercholesterolemia.
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Figure 5 | Comparison of the levels of paraoxonase activity
between rs662 genotypes. P-value shows the comparison among
rs662 genotype by ANOVA with the Bonferroni test as a post hoc test.
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Figure 6 | Immunohistochemistry for PON1 in human biopsy
specimens. (a) 54-year-old male with benign nephrosclerosis,
magnification 400, (b) 74-year-old female with diabetic
nephropathy, magnification 200.
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pressure levels. The adjustment with these risk factors might
underestimate the effect of PON1 on the development
of CKD.
As reported earlier in vivo and in vitro,12,16,17 the close
relation between PON1 genotype and its activity was
confirmed in this study. Therefore, it is speculated that
PON1 genotype is linked to renal injury through the levels of
PON1 activity. At first, we hypothesized that PON1 might
affect vascular damage by modulating the oxidation of lipids.
However, the relation of PON1 genotype with Malondialde-
hyde–low-density lipoprotein levels was not detected suggest-
ing that Malondialdehyde–low-density lipoprotein might not
be the main target of its antioxidant activity. The PON1 has a
potential to hydrolyze many substrates including a variety of
oxidized lipids,9 therefore other substrates or mechanism
might be involved in its vasoprotective effect.
The reason why the relations between PON1 genotype and
CKD were detected only in women is unknown. However, a
similar finding was documented by Christiansen et al.18 that
rs662 genotype was related to a survival rate only in women,
but not in men. The risk factors for renal injury such as
hypertension, diabetes, and smoking were more common in
men than in women and might abrogate the beneficial effect
of PON1. Especially, smoking is reported to reduce PON1
activity.19 In this population the prevalence of current
smokers were higher in men (34.3%) than in women
(5.4%). These factors or other gender-associated factors
might alter the relation of PON1 with the susceptibility to
CKD. To clarify this point further study is necessary.
There are several limitations in this study. First, the
subjects with serious diseases including stroke and myocar-
dial infarction are usually followed by their doctors and do
not attend this community-based health check. Therefore,
the effect of PON1 genotype on CVD might be under-
estimated in this study. This might be one of the possible
reasons that the relationship between SNP rs662 genotype
and CVD described in previous studies20–22 was not observed
in this population. Second, this finding was obtained from
our single cohort. To confirm the effect of PON1 on CKD it
should be verified in another independent cohort. However,
the allele frequency of rs662 greatly depends on ethnicity and
the frequency of A allele is much lower in Japanese (0.34)
than other ethnicities (0.69–0.76).23 Therefore, the relation
between PON1 genotype and CKD might be modified by
ethnicities.
The precise mechanisms how PON1 attenuate the vascular
damage is not fully understood; however, the overexpression
of PON1 significantly reduces atherogenic lesions in the
animal model.6 This suggests that PON1 might be a potential
therapeutic target for the prevention and treatment of CKD
as well as CVD in future.
In conclusion, this study revealed that PON1 genotype
was related to albuminuria and renal function, possibly
through the modulation of renal vascular damage. The PON1
might be one of the key players in the common pathway to
CKD and CVD.
MATERIALS AND METHODS
Study population
This study is part of the comprehensive ‘Molecular epidemiological
study utilizing the regional characteristics’ of 21st Century Centers
of Excellence (COE) and global COE Program in Japan as previously
described in detail.24 The aim of this study is to determine the
association between genetic variants and CKD in a general
population in Japan. This study is a design-incorporated baseline
survey that consisted of a self-administered questionnaire on
lifestyle, blood pressure measurement, anthropometrical measure-
ment, and collections of blood and urine specimens from
participants at annual health checkup. Genomic DNA was extracted
from peripheral blood samples.15
The survey population in this study is the general population
over 40-year-olds in Takahata, Japan. In 2004 and 2005, a total of
3115 subjects (mean age 63; men 1380; women 1735) took part in
the program and agreed to join the study. This study was approved
by the institutional ethical committee. All participants gave written
informed consent.
Among 3115 subjects, 146 subjects were excluded from the
present analysis due to their incomplete data. Thus, 2968 subjects
were entered into final analyses (mean age 63 years; men 1343;
women 1625).
Measurement
Clinical information concerning medical history, current medica-
tion, smoking habits, and alcohol intake was obtained from a self-
reported questionnaire. Blood pressures were determined by using a
mercury manometer, in subjects who had rested in a sitting position
for at least 5 min before the measurement. Hypertension was defined
as systolic blood pressure X140 mm Hg and/or diastolic blood
pressure X90 mm Hg, and/or the use of antihypertensive medica-
tion. Body mass index was calculated from weight and height
measures as weight (kg) divided by the square of height (m2).
Obesity was specified as body mass indexX25.0 kg/m2 both in men
and in women. Diabetes was ascertained either by self-reported
physical diagnosis or by a measure of fasting blood sugarX126 mg/
100 ml or HbA1c value X6.5%. The subjects with impaired glucose
tolerance were included in this analysis. Hypercholesterolemia was
ascertained by a measure of serum total cholesterol X220 mg/
100 ml, and/or the use of antihyperlipidemic medication. Urine
albumin–creatinine ratio was calculated from a single spot urine
specimen collected in the morning. Urine albumin concentration
was determined by an immunoturbidimetry. Albuminuria was
defined as urine albumin–creatinine ratio X20 mg/g in men and
X30 mg/g in women, respectively.25 Serum creatinine was measured
by an enzymatic method and eGFR was obtained using the modified
MDRD equation with Japanese modification.26 The paraoxonase
activity was measured by the rate of generation of p-nitrophenol
from paraoxon (BML Inc., Tokyo, Japan).27 Malondialdehyde—low-
density lipoprotein was examined by ELISA (SRL Inc., Tokyo,
Japan).
SNP selection and genotyping
We have utilized dbSNP database of the NCBI (http://
www.ncbi.nlm.nih.gov/SNP/) and International HapMap Project
(http://www.hapmap.org/index.html) to extract all SNPs of PON1
gene with a minor allele frequency greater than 0.1 in the Japanese
general population. Seven SNPs were selected and have been
genotyped. All SNPs gave accurate typing (call rate 499%) and
were used in this study.
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Genotypes for these seven SNPs were determined by an Invader
assay (Third Wave Technologies, Madison, WI, USA)28,29 and
TaqMan allelic discrimination assay.30 Reagents were purchased
from Applied Biosystems (Foster City, CA, USA). TaqMan probes
were designed and synthesized by Applied Biosystems, and
distinguish the SNPs at the end of a polymerase chain reaction.
One allelic probe was labeled with fluorescent FAM dye and the
other with the fluorescent VIC dye. Polymerase chain reaction was
performed by TaqMan Universal Master Mix without UNG (Applied
Biosystems) with polymerase chain reaction primers at a concentra-
tion of 900 nM and TaqMan MGB probes at a concentration of
200 nM. Reactions were performed in 384-well formats in a total
reaction volume of 3 ml using 3.0 ng of genomic DNA. The plates
were then placed in a GeneAmp PCR System 9700 (Applied
Biosystems) and heated at 951C for 10 min, followed by 40 cycles at
921C for 15 s and 601C for 1 min, with a final soak at 251C. The
plates were read by the Prism 7900HT instrument (Applied
Biosystems) where the fluorescence intensity in each well of the
plate was read.28 Fluorescence data files from each plate were
analyzed by the SDS 2.0 allele calling software (Applied Biosystems).
Several data (signal intensity) were eliminated to preserve the
reliability of the assay system (missing data are guaranteed to be less
than 1%).
Statistical analyses
We used a w2 test to evaluate differences in proportions and an
ANOVA with the Bonferroni test as a post hoc test to evaluate
differences in means. For some of the clinical and biochemical traits
that did not distribute normally, we applied a non-parametric
Kruskal–Wallis test. To confirm the Hardy–Weinberg equilibrium
among genotypes, a w2 test was used (PX0.05). LD for the
combination of variations was tested by D’ and r2 by using Haploview.
Data are expressed as mean±s.d. except as otherwise indicated. A
significant difference was defined as Po0.05. All statistical analysis was
performed using SPSS version 15.0.1J (SPSS Inc., Chicago, IL, USA).
Immunohistochemistry
Anti-PON1 goat antibody and peroxidase-conjugated donkey anti-
goat immunoglobulin were purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA). Immunohistochemical staining was
performed on frozen sections of human biopsy specimen using
enzyme-labeled antibody method. Frozen sections were air-dried
and fixed in acetone for 5 min. Endogenous peroxide activity was
quenched by incubating sections in 0.3% H2O2/methanol for
20 min. Sections were incubated with an antibody against PON1
(dilution 1:100) at 41C overnight. After incubating with secondary
antibody at a concentration of 1:100 for 1 h, immunoreaction
products were developed using 3,30-diaminobenzidine as the
chromogen, with standardized development times. Sections were
then counterstained with hematoxylin acetate. Negative controls
were prepared by using irrelevant normal goat IgG as a primary
antibody.
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